Abivax Triggers MACD Death Cross, KDJ Death Cross on 15-Minute Chart
ByAinvest
Tuesday, Oct 21, 2025 2:32 pm ET1min read
ABVX--
The MACD Death Cross occurs when the MACD line crosses below the signal line, indicating a bearish signal. Similarly, the KDJ Death Cross happens when the KDJ line crosses below the signal line, reinforcing the bearish momentum. These indicators are widely used by technical analysts to predict changes in stock price trends.
Analysts from various financial institutions have initiated coverage on Abivax, with mixed opinions on the stock's potential. On October 13, 2025, Etzer Darout from Barclays initiated coverage on Abivax with an Overweight rating and a $142 price target. However, the recent technical indicators suggest a potential downward trend, which could impact the stock's price.
Investors and financial professionals should closely monitor Abivax's stock performance and consider the implications of these technical indicators. While the Overweight rating from Barclays suggests a potential for growth, the recent technical signals indicate a need for caution.
According to Abivax's 15-minute chart, a MACD Death Cross and KDJ Death Cross were triggered at 14:30 on October 21, 2025. This indicates that the stock price has the potential to continue falling and that the momentum is shifting towards the downside, with a potential for further decreases.
On October 21, 2025, Abivax Société Anonyme (NASDAQ:ABVX) experienced a significant technical shift in its stock price. According to the 15-minute chart, both the MACD (Moving Average Convergence Divergence) and the KDJ (Kaufman Adaptive Moving Average) indicators triggered a "Death Cross" at 14:30. This technical pattern suggests a potential continuation of the downward trend, indicating a shift in momentum towards the downside.The MACD Death Cross occurs when the MACD line crosses below the signal line, indicating a bearish signal. Similarly, the KDJ Death Cross happens when the KDJ line crosses below the signal line, reinforcing the bearish momentum. These indicators are widely used by technical analysts to predict changes in stock price trends.
Analysts from various financial institutions have initiated coverage on Abivax, with mixed opinions on the stock's potential. On October 13, 2025, Etzer Darout from Barclays initiated coverage on Abivax with an Overweight rating and a $142 price target. However, the recent technical indicators suggest a potential downward trend, which could impact the stock's price.
Investors and financial professionals should closely monitor Abivax's stock performance and consider the implications of these technical indicators. While the Overweight rating from Barclays suggests a potential for growth, the recent technical signals indicate a need for caution.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet